The p53 network in head and neck cancer

被引:95
作者
Gasco, M
Crook, T
机构
[1] S Croce Gen Hosp, Dept Med Oncol, I-12100 Cuneo, Italy
[2] Univ London Imperial Coll Sci & Technol, Ludwig Inst Canc Res, Fac Med, London W2 1PG, England
关键词
p53; head and neck cancer; tumour suppressor gene;
D O I
10.1016/S1368-8375(02)00163-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and, despite advances in treatment, still represents a clinical challenge. Inactivation of one or more components of the p53 network is an extremely common event in human neoplasia. In HNSCC, disabling of p53 occurs in a high proportion of cases by mutation in the p53 gene, but other mechanisms of inactivation, such as the presence of human papillomavirus (HPV) and molecular abnormalities in other components of the pathway, are also recognised. The frequent changes occurring in the p53 pathway in HNSCC imply that molecular genetic and immunocytochemical analysis of this critical tumour suppressor network may be of diagnostic and prognostic utility in the clinical management of HNSCC. Further, these changes also provide targets for the development of novel therapeutic approaches to this increasingly common cancer, in which clinical cure for advanced disease remains an elusive goal. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:222 / 231
页数:10
相关论文
共 92 条
[1]   MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications [J].
Agarwal, S ;
Mathur, M ;
Srivastava, A ;
Ralhan, R .
ORAL ONCOLOGY, 1999, 35 (02) :209-216
[2]   TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck [J].
Alsner, J ;
Sorensen, SB ;
Overgaard, J .
RADIOTHERAPY AND ONCOLOGY, 2001, 59 (02) :179-185
[3]   Post-translational modifications and activation of p53 by genotoxic stresses [J].
Appella, E ;
Anderson, CW .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (10) :2764-2772
[4]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[5]   Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma [J].
Bourhis, J ;
Lubin, R ;
Roche, B ;
Koscielny, S ;
Bosq, J ;
Dubois, I ;
Talbot, M ;
Marandas, P ;
Schwaab, G ;
Wibault, P ;
Luboinski, B ;
Eschwege, F ;
Soussi, T .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) :1228-1233
[6]   GENE-MUTATIONS IN SALIVA AS MOLECULAR MARKERS FOR HEAD AND NECK SQUAMOUS-CELL CARCINOMAS [J].
BOYLE, JO ;
MAO, L ;
BRENNAN, JA ;
KOCH, WM ;
EISELE, DW ;
SAUNDERS, JR ;
SIDRANSKY, D .
AMERICAN JOURNAL OF SURGERY, 1994, 168 (05) :429-432
[7]  
BOYLE JO, 1993, CANCER RES, V53, P4477
[8]  
BRACHMAN DG, 1992, CANCER RES, V52, P4832
[9]   Predictive factors in head and neck cancer [J].
Bradford, CR .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (04) :777-+
[10]   Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma [J].
Bradley, G ;
Irish, J ;
MacMillan, C ;
Mancer, K ;
Witterick, I ;
Hartwick, W ;
Gullane, P ;
Kamel-Reid, S ;
Benchimol, S .
ONCOGENE, 2001, 20 (05) :654-658